Doximity, Inc. (NASDAQ:DOCS) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its position in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 10.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 444,596 shares of the company's stock after selling 53,460 shares during the period. JPMorgan Chase & Co. owned about 0.24% of Doximity worth $23,737,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the company. Global Retirement Partners LLC increased its stake in Doximity by 468.1% in the fourth quarter. Global Retirement Partners LLC now owns 534 shares of the company's stock valued at $29,000 after purchasing an additional 440 shares during the period. UMB Bank n.a. lifted its holdings in Doximity by 69.1% in the fourth quarter. UMB Bank n.a. now owns 575 shares of the company's stock valued at $31,000 after acquiring an additional 235 shares during the period. Larson Financial Group LLC lifted its stake in shares of Doximity by 49.4% in the fourth quarter. Larson Financial Group LLC now owns 756 shares of the company's stock valued at $40,000 after purchasing an additional 250 shares during the period. Optimum Investment Advisors purchased a new stake in shares of Doximity during the 4th quarter worth approximately $43,000. Finally, Morse Asset Management Inc purchased a new stake in Doximity during the third quarter worth $46,000. Institutional investors and hedge funds own 87.19% of the company's stock.

Insider Activity at Doximity

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the firm's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total value of $1,152,400.00. Following the sale, the director now directly owns 6,360 shares in the company, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 37.40% of the company's stock.

Analysts Set New Price Targets

DOCS has been the topic of several recent research reports. The Goldman Sachs Group upped their price target on shares of Doximity from $58.00 to $80.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Needham & Company LLC lifted their price target on Doximity from $65.00 to $82.00 and gave the company a "buy" rating in a report on Friday, February 7th. Bank of America upped their price objective on Doximity from $54.00 to $57.00 and gave the stock a "neutral" rating in a report on Monday, January 6th. Raymond James restated an "outperform" rating and issued a $83.00 price target (up previously from $65.00) on shares of Doximity in a report on Friday, February 7th. Finally, Stephens initiated coverage on Doximity in a research report on Friday, December 20th. They issued an "equal weight" rating and a $55.00 price objective on the stock. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $64.72.

Doximity Price Performance

DOCS traded up $0.46 during trading hours on Tuesday, hitting $53.06. 268,937 shares of the stock were exchanged, compared to its average volume of 1,973,571. The stock has a 50-day simple moving average of $64.63 and a 200-day simple moving average of $55.65. Doximity, Inc. has a 12 month low of $22.96 and a 12 month high of $85.21. The stock has a market cap of $9.91 billion, a price-to-earnings ratio of 53.06, a price-to-earnings-growth ratio of 4.10 and a beta of 1.41.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.